OTC Monograph Purity Concern Among Problems Noted In US FDA FY21 Drug Quality Review

Data Point To More Recalls As Inspections Increase, Problems With Firms' Investigations

Results from FDA requests sent to 13 manufacturers of 15 commonly used OTC drugs for data on the state of organic impurity control for monograph products. • Source: Shutterstock
HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation